Media store

Media Releases

Published on: 4 December 2019

FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and ...

Published on: 2 December 2019

Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine

Roche announced today that data from SAkuraSky, a pivotal phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were ...

Published on: 25 November 2019

FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor ...

Upcoming Events

All

17March

Annual General Meeting (tentative)

(CEST)

Basel, Switzerland

add to calendar

22April

First quarter sales 2020

(CEST)

Basel

23July

Half year results 2020

(CEST)

Basel

16October

Third quarter sales 2020

(GMT)

Basel

Topics

Media contacts

For media requests

+41 61 688 8888

Media Relations Team

For all general enquiries

Please call the Roche switchboard on
Phone:+41 61 688 11 11